References
- Sangle NA, Perkins SL. Core-binding factor acute myeloid leukemia. Arch Pathol Lab Med 2011;135:1504–1509.
- Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol 2002;39:6–11.
- Takahashi S. Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 2011;4:36.
- Kales SC, Ryan PE, Nau MM, . Cbl and human myeloid neoplasms: the cbl oncogene comes of age. Cancer Res 2010;70: 4789–4794.
- Ogawa S, Shih LY, Suzuki T, . Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res 2010;16:3825–3831.
- Sargin B, Choudhary C, Crosetto N, . Flt3-dependent transformation by inactivating c-cbl mutations in AML. Blood 2007;110:1004–1012.
- Caligiuri MA, Briesewitz R, Yu J, . Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 2007;110:1022–1024.
- Peschard P, Park M. Escape from cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003;3:519–523.
- Aranaz P, Hurtado C, Erquiaga I, . CBL mutations in myeloproliferative neoplasms are also found in its proline-rich domain and in patients with the V617FJAK2. Haematologica 2012 Feb 7. [Epub ahead of print]
- Abbas S, Rotmans G, Lowenberg B, . Exon 8 splice site mutations in the gene encoding the E3-ligase CBL are associated with core binding factor acute myeloid leukemias. Haematologica 2008;93:1595–1597.
- Reindl C, Quentmeier H, Petropoulos K, . CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009;15:2238–2247.
- Sanada M, Suzuki T, Shih LY, . Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 2009;460: 904–908.
- Makishima H, Cazzolli H, Szpurka H, . Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies. J Clin Oncol 2009;27: 6109–6116.
- Fernandes MS, Reddy MM, Croteau NJ, . Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism. J Biol Chem 2010;285:32596–32605.
- Haferlach C, Dicker F, Kohlmann A, . AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions. Leukemia 2010;24: 1065–1069.